NASDAQ · Health care

Natera, Inc. (NTRA)

Natera, Inc. brought in $2.7B of revenue over the twelve months to June 30, 2026, up 37.8% from a year earlier. It posted a net loss of $192.3M. Operating cash flow minus capital spending left $109.1M of free cash flow in fiscal 2025. At June 30, 2026 it held $1.1B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Watch NTRA in 60 seconds Follow NTRA

Price

$425.64

+3.73% on the day · October 5, 2026

52-week range $167.33 to $427.47

Market cap

$61.4B

Revenue (last 12 months)

$2.7B

+37.8% year on year

Net margin

-7.1%

Key facts about Natera, Inc.

Net worth: Natera, Inc. has a market value (market cap) of $61.4B at the latest share price, and shareholders' equity of $1.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $2.3B (+35.9% year on year), with a net loss of $208.2M. Over the 12 months to June 30, 2026: revenue $2.7B, net loss $192.3M.
Cash flow: In fiscal 2025 operations brought in $215.3M of cash; after $106.2M of capital spending, free cash flow was $109.1M.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report: Natera, Inc.'s next report is expected around November 5, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Natera, Inc. does

Natera provides cell-free DNA testing services for women's health, oncology, and organ health. Its offerings include non-invasive prenatal tests, carrier screenings, hereditary cancer screenings, minimal residual disease monitoring for cancer patients, and donor-derived cell-free DNA tests for kidney and heart transplant recipients. Its shares trade on NASDAQ under the ticker NTRA.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$2.3B	-$309.9M	-$208.2M	-$1.52	$109.1M
2024	$1.7B	-$222.3M	-$190.4M	-$1.53	$69.2M
2023	$1.1B	-$446.2M	-$434.8M	-$3.78	-$286.2M
2022	$820.2M	-$541M	-$547.8M	-$5.57	-$479.2M
2021	$625.5M	-$468.2M	-$471.7M	-$5.21	-$376.3M
2020	$391M	-$216.3M	-$229.7M	-$2.84	-$202.1M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Where NTRA ranks in Health care

Revenue$2.3B

#107 of 750 in Health care · Top 14%

Revenue growth+35.9%

#123 of 532 in Health care · Top 23%

Net margin-9.0%

#280 of 543 in Health care · Bottom 49%

Free cash flow margin4.7%

#181 of 489 in Health care · Top 37%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Natera, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 7, 2026
Employee stock plan registration S-8
August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 38% to $752.8M versus the same quarter last year; diluted EPS -$0.47 versus -$0.74.
August 6, 2026
Quarterly results 8-K
July 6, 2026
Executive or director change 8-K
June 16, 2026
Executive or director change 8-K/A
June 16, 2026
Executive or director change 8-K
June 5, 2026
Executive or director change 8-K
May 8, 2026
Quarterly report 10-Q · period to March 31, 2026Revenue rose 39% to $696.6M versus the same quarter last year; diluted EPS -$0.60 versus -$0.50.
May 7, 2026
Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 2, 2026. Insider transactions on SEC

What is NTRA worth? A DCF from its reported cash flow

Insider trades

What the people running Natera, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $85.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$85.7M

last 90 days

Net sold

259,392

$85.7M

Date	Insider	What	Shares	Price	Value	Filing
October 1, 2026	Chapman Steven LeonardCEO AND PRESIDENT, Director	Soldpre-planned (10b5-1)	1,273	$413.31	$526.1K	Form 4
October 1, 2026	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS	Soldpre-planned (10b5-1)	200	$411.62	$82.3K	Form 4
October 1, 2026	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS	Soldpre-planned (10b5-1)	954	$413.11	$394.1K	Form 4
October 1, 2026	Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS	Soldpre-planned (10b5-1)	1,846	$415.07	$766.2K	Form 4
September 23, 2026	Sheena JonathanDirector	Soldpre-planned (10b5-1), indirect	400	$385.10	$154K	Form 4
September 23, 2026	Sheena JonathanDirector	Soldpre-planned (10b5-1), indirect	2,175	$386.71	$841.1K	Form 4
September 23, 2026	Sheena JonathanDirector	Soldpre-planned (10b5-1), indirect	2,734	$387.65	$1.1M	Form 4
September 23, 2026	Sheena JonathanDirector	Soldpre-planned (10b5-1), indirect	1,293	$388.71	$502.6K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns NTRA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
T. Rowe Price Associates, Inc.13G, passive	6.3%	9,021,825	August 14, 2026
Vanguard Capital Management13G, passive	5.08%	7,205,939	April 30, 2026

Latest filings below 5%: The Vanguard Group 0% (March 27, 2026); Alger Associates, Inc. 3.2% (November 14, 2024).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 846 managers reported a position.

Holder	Shares	Value	Change on quarter
Jpmorgan Chase & Co	12,865,346	$3.51B	-521,321
BlackRock, Inc.	10,914,608	$2.96B	+237,270
Vanguard Capital Management LLC	6,228,216	$1.69B	+219,720
Vanguard Portfolio Management LLC	5,782,640	$1.57B	+137,945
Fmr LLC	5,451,396	$1.48B	+2,897,142
Wellington Management Group Llp	4,040,738	$1.1B	-727,855
State Street Corp	3,655,618	$992.3M	+238,146
Geode Capital Management, LLC	2,750,013	$744.6M	-25,915
Franklin Resources Inc	2,725,903	$739.9M	+240,578
Castle Hook Partners LP	2,596,276	$704.8M	+66,466
Coatue Management LLC	2,505,090	$680M	-36,752
Aqr Capital Management LLC	2,344,570	$628.1M	+70,579
Farallon Capital Management, L.L.C.	2,218,366	$602.2M	-989,000
Massachusetts Financial Services Co	1,971,391	$535.1M	-68,715
Norges Bank	1,828,122	$496.2M	new
Fred Alger Management, LLC	1,778,009	$482.6M	+21,537
Goldman Sachs Group Inc	1,720,152	$466.9M	+952,921
Sofinnova Investments, Inc.	1,550,280	$420.8M	0
Capital World Investors	1,504,387	$408.4M	+36,412
Arrowstreet Capital, Limited Partnership	1,503,706	$408.2M	+311,974

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

16 insiders reported holding 4,114,502 shares in total, about $1.75B at the last price.

Holder	Shares	As of
Rabinowitz MatthewEXECUTIVE CHAIRMAN, Director	2,125,394	September 15, 2026
Botha RoelofDirector	1,080,7831,076,198 held indirectly	June 26, 2026
Sheena JonathanDirector	230,3149,000 held indirectly	September 23, 2026
Fesko JohnPRESIDENT, CHIEF BUS. OFFICER	197,257	August 10, 2026
Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER	170,073	August 3, 2026
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS	106,914	October 1, 2026
Chapman Steven LeonardCEO AND PRESIDENT, Director	96,926	October 1, 2026
Brophy Michael BurkesCHIEF FINANCIAL OFFICER	51,637	August 4, 2026
Baynes Roy D.Director	20,158	June 26, 2026
Marcus Gail BoxerDirector	7,852	June 26, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about NTRA

What does Natera, Inc. do?

What is Natera, Inc.'s net worth?

Natera, Inc. has a market value (market cap) of $61.4B at the latest share price, and shareholders' equity of $1.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Natera, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $192.3M on revenue of $2.7B.

How much revenue does Natera, Inc. make?

Over the twelve months to June 30, 2026 Natera, Inc. reported revenue of $2.7B. That is 37.8% more than a year earlier.

When did Natera, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.

When is Natera, Inc.'s next earnings report?

Natera, Inc.'s next report is expected around November 5, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Labcorp Holdings Inc.

DGX

Quest Diagnostics Inc

Guardant Health, Inc.

CAI

Caris Life Sciences, Inc.

Compare NTRA with

Compare NTRA with any company

Follow NTRA

Get an email when Natera, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow NTRA: get an email when it files

Where the numbers come from

Financial figures are the values Natera, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.